Metabolic Disorder Therapeutics Market Size, Share, Growth Analysis, By Disease(Lysosomal Storage Diseases, Gaucher’s Disease, Metachromatic Leukodystrophy, Hurler - Scheie), By Therapy Type(Enzyme Replacement Therapy, Cellular Transplantation, Small Molecule Based Therapy, Substrate Reduction Therapy), By Regional(North America, The U.S., Canada, Europe) - Industry Forecast 2025-2032

Metabolic Disorder Therapeutics Market Insights

Market Overview:

Initiating at a valuation of USD 49.65 billion in 2017, the global metabolic disorder therapeutics market is poised for an upward trajectory, projected to sustain a notable Compound Annual Growth Rate (CAGR) of 7.56% throughout the forecast period. This ascent is galvanized by a confluence of pivotal factors. The surging demand for one-time therapeutic interventions tailored for metabolic disorders stands as a chief propeller, promising effective treatment regimens for patients. A parallel narrative is woven by the escalating prevalence of lifestyle-related diseases, such as diabetes and obesity, as a result of changing global lifestyles. Projections from governmental bodies and healthcare organizations paint a vivid picture, estimating that over half a billion individuals could be grappling with these conditions by 2040. Moreover, the rising incidence of inherited metabolic disorders, spurred by lifestyle shifts, lends additional impetus to the market's growth, painting a comprehensive landscape poised for positive transformation.

Metabolic Disorder Therapeutics Market, Forecast & Y-O-Y Growth Rate, 2020 - 2028

To get more reports on the above market click here to
GET FREE SAMPLE

This report is being written to illustrate the market opportunity by region and by segments, indicating opportunity areas for the vendors to tap upon. To estimate the opportunity, it was very important to understand the current market scenario and the way it will grow in future.

Production and consumption patterns are being carefully compared to forecast the market. Other factors considered to forecast the market are the growth of the adjacent market, revenue growth of the key market vendors, scenario-based analysis, and market segment growth.

The market size was determined by estimating the market through a top-down and bottom-up approach, which was further validated with industry interviews. Considering the nature of the market we derived the Pharmaceuticals by segment aggregation, the contribution of the Pharmaceuticals in Pharmaceuticals, Biotechnology & Life Sciences and vendor share.

To determine the growth of the market factors such as drivers, trends, restraints, and opportunities were identified, and the impact of these factors was analyzed to determine the market growth. To understand the market growth in detail, we have analyzed the year-on-year growth of the market. Also, historic growth rates were compared to determine growth patterns.

Segmentation Analysis:

The Metabolic Disorder Therapeutics Market is segmented by Disease, Therapy Type, Regional. We are analyzing the market of these segments to identify which segment is the largest now and in the future, which segment has the highest growth rate, and the segment which offers the opportunity in the future.

Metabolic Disorder Therapeutics Market Basis Point Share Analysis, 2021 Vs. 2028

To get detailed analysis on all segments
BUY NOW

Based on Disease the market is segmented as, Lysosomal Storage Diseases, Gaucher’s Disease, Metachromatic Leukodystrophy, Hurler - Scheie, Sanfilipo A, Others, Diabetes, Obesity, Inherited Metabolic Disorders, Hypercholesterolemia
Based on Therapy Type the market is segmented as, Enzyme Replacement Therapy, Cellular Transplantation, Small Molecule Based Therapy, Substrate Reduction Therapy, Gene Therapy, Drug Therapy, Route of Administration, Oral, Parenteral, Others
Based on Regional the market is segmented as, North America, The U.S., Canada, Europe, Germany, U.K., Asia Pacific, Japan, China, Latin America, Brazil, Middle East & Africa, South Africa, KEY MARKET PLAYERS, Novo Nordisk A/S, Sanofi S.A., Boehringer Ingelheim GmbH, Eli Lilly and Company, Merck KgaA, Amgen, Inc., AstraZeneca PLC, Actelion Pharmaceuticals Ltd., Shire PLC, AbbVie, Inc., Biocon Ltd., BioMarin Pharmaceutical, Inc., Bristol-Myers Squibb Company, Cipla, Inc.

Regional Analysis:

Metabolic Disorder Therapeutics Market is being analyzed by North America, Europe, Asia-Pacific (APAC), Latin America (LATAM), Middle East & Africa (MEA) regions. Key countries including the U.S., Canada, Germany, France, UK, Italy, Spain, China, India, Japan, Brazil, GCC Countries, and South Africa among others were analyzed considering various micro and macro trends.

Metabolic Disorder Therapeutics Market Attractiveness Analysis, By Region 2020-2028

To know more about the market opportunities by region and country, click here to
REQUEST FREE CUSTOMIZATION

Metabolic Disorder Therapeutics Market : Risk Analysis

SkyQuest's expert analysts have conducted a risk analysis to understand the impact of external extremities on Metabolic Disorder Therapeutics Market. We analyzed how geopolitical influence, natural disasters, climate change, legal scenario, economic impact, trade & economic policies, social & ethnic concerns, and demographic changes might affect Metabolic Disorder Therapeutics Market's supply chain, distribution, and total revenue growth.

Competitive landscaping:

To understand the competitive landscape, we are analyzing key Metabolic Disorder Therapeutics Market vendors in the market. To understand the competitive rivalry, we are comparing the revenue, expenses, resources, product portfolio, region coverage, market share, key initiatives, product launches, and any news related to the Metabolic Disorder Therapeutics Market.

To validate our hypothesis and validate our findings on the market ecosystem, we are also conducting a detailed porter's five forces analysis. Competitive Rivalry, Supplier Power, Buyer Power, Threat of Substitution, and Threat of New Entry each force is analyzed by various parameters governing those forces.

Key Players Covered in the Report:

rview
The global metabolic disorder therapeutics market size was valued at USD 49.65 billion in 2017 and is expected to register a CAGR of 7.56% over the forecast period. Increasing demand for one-time therapies for metabolic disorders and the rising prevalence of lifestyle diseases are the key factors that are expected to boost the growth of this market. Various governments and healthcare associations around the world have estimated that more than half a billion individuals are to be affected by obesity and diabetes by 2040. Also, rising incidences of inherited metabolic diseases due to changing lifestyles are likely to propel the market growth.
As has been observed in recent years, the cases of diabetes have been increasing and many of the countries might face a potential metabolic disorder epidemic. Many of the industrial countries are concerned with the chronic obesity epidemic with the U.S. leading in the number of obese cases. In the U.S. alone, an obese person on average spends around USD 1500 on medical expenses.
Over the years, the global economic condition has improved, especially in developing countries, which have a high number of cases of metabolic diseases. Researchers are urging governments across the globe to take action and come up with studies and solutions to reduce obesity and diabetes. For instance, scientists say that one in three individuals is obese and there have never been reports stating the reduction in obesity numbers. These factors are driving obesity segment growth.
Other factors that are propelling the market growth are the rapidly aging population, sedentary lifestyles, and increasing cases of smoking and other metabolic pathway restricting practices. Diabetes has become a global epidemic with more than 5% of the population affected by the disease requiring constant medication to battle certain fatal conditions. For instance, in 2016, around 1.5 million deaths occurred directly due to diabetes.
Disease Insights
Based on disease, the market is categorized into diabetes, lysosomal disorders, hypercholesterolemia, obesity, and inherited metabolic disorders. These diseases are mostly inherited from the older generation through a faulty gene and some show immediate effects like the lysosomal disorders, while some show up later due to aging. For instance, diabetes might not be diagnosed up to a certain age.
Diabetes was estimated to be the largest segment in 2017 due to the wide usage of metabolic disease therapies in anti-diabetic drugs and injections to control the blood sugar levels. In diabetes, constant ingestion of metabolic regulators is essential. This factor makes it the largest revenue-generating segment. However, the obesity segment is expected to witness the fastest growth over the forecast period due to increasing lifestyle changes and unhealthy eating habits.
Therapy Insights
The therapy segment is further categorized into enzyme replacement therapy, cellular transplantation, substrate reduction therapy, small molecule-based therapy, gene therapy, and drug therapy. Except for drug therapy, all the other therapies are novel and cutting-edge, which makes then more effective in treating metabolic diseases. However, the downside of these therapies is high costs and a lack of solid scientific backup. For instance, enzyme replacement therapy costs around 300,000 per year as the treatment should go on continuously at least once or twice a week.
Thus, drug therapy held the highest market share due to its extensive usage as a result if ease of administration and high-reliability rate. This therapy is expected to maintain its growth even during the forecast period owing to its advanced ways of administering medications without disturbing day-to-day patient lives. Moreover, the introduction of smart drug delivery devices and smart dosage control methods are projected to drive the segment further.
Route of Administration Insights
Based on the route of administration, the market is segmented into oral, parenteral, and other routes of administration. The oral route of administration segment was the key revenue-generating segment due to wide usage in diabetes and hypercholesterolemia treatments. The rise in demand for safe and smart drug delivery has driven the growth in this segment because of the ease of use, reliability, and proven results offered by the oral route of administration.
The other segment is also likely to witness significant growth over the forecast period as researchers are continuously striving for better medication and therapy that can eliminate the need for lifelong diagnosis and multiple dosage therapy. In recent years, due to the advances in diagnostics, greater emphasis on groundbreaking therapies, like gene therapy, has been observed. This is projected to lead the segment growth shortly.
Regional Insights
North America is the dominant region of this market due to the presence of major companies. Increasing prevalence of obesity and diabetes in the region is another factor responsible for its largest share. High healthcare expenditure and rising awareness about metabolic disorders are expected to drive the regional market further.
Asia Pacific is said to witness the fastest CAGR of 8.27% during the estimated time owing to the rapid economic development in this region. Changing lifestyles, leading to a rise in obesity, diabetes, and hypercholesterolemia diseases, along with increased disposable income levels are driving the APAC market.
Market Share Insights
Expansion of product portfolios and M&A are the key strategies undertaken by most of these companies. For instance, in 2017, Boehringer Ingelheim, in collaboration with Eli Lily and Company, had announced positive data about the clinical development of Jardiance for the reduction of cardiovascular deaths in adults with type 2 diabetes and peripheral artery disease.
KEY MARKET SEGMENTS
By Disease
Lysosomal Storage Diseases
Gaucher’s Disease
Metachromatic Leukodystrophy
Hurler - Scheie
Sanfilipo A
Others
Diabetes
Obesity
Inherited Metabolic Disorders
Hypercholesterolemia
By Therapy Type
Enzyme Replacement Therapy
Cellular Transplantation
Small Molecule Based Therapy
Substrate Reduction Therapy
Gene Therapy
Drug Therapy
Route of Administration
Oral
Parenteral
Others
By Regional
North America
The U.S.
Canada
Europe
Germany
U.K.
Asia Pacific
Japan
China
Latin America
Brazil
Middle East & Africa
South Africa
KEY MARKET PLAYERS
Novo Nordisk A/S
Sanofi S.A.
Boehringer Ingelheim GmbH
Eli Lilly and Company
Merck KgaA
Amgen, Inc.
AstraZeneca PLC
Actelion Pharmaceuticals Ltd.
Shire PLC
AbbVie, Inc.
Biocon Ltd.
BioMarin Pharmaceutical, Inc.
Bristol-Myers Squibb Company
Cipla, Inc.
CymaBay Therapeutics, Inc."

SkyQuest's Expertise:

The Metabolic Disorder Therapeutics Market is being analyzed by SkyQuest's analysts with the help of 20+ scheduled Primary interviews from both the demand and supply sides. We have already invested more than 250 hours on this report and are still refining our date to provide authenticated data to your readers and clients. Exhaustive primary and secondary research is conducted to collect information on the market, peer market, and parent market.

Our cross-industry experts and revenue-impact consultants at SkyQuest enable our clients to convert market intelligence into actionable, quantifiable results through personalized engagement.

Scope Of Report

Report Attribute	Details
The base year for estimation	2021
Historical data	2016 – 2022
Forecast period	2022 – 2028
Report coverage	Revenue forecast, volume forecast, company ranking, competitive landscape, growth factors, and trends, Pricing Analysis
Segments covered	By Disease - Lysosomal Storage Diseases, Gaucher’s Disease, Metachromatic Leukodystrophy, Hurler - Scheie, Sanfilipo A, Others, Diabetes, Obesity, Inherited Metabolic Disorders, Hypercholesterolemia By Therapy Type - Enzyme Replacement Therapy, Cellular Transplantation, Small Molecule Based Therapy, Substrate Reduction Therapy, Gene Therapy, Drug Therapy, Route of Administration, Oral, Parenteral, Others By Regional - North America, The U.S., Canada, Europe, Germany, U.K., Asia Pacific, Japan, China, Latin America, Brazil, Middle East & Africa, South Africa, KEY MARKET PLAYERS, Novo Nordisk A/S, Sanofi S.A., Boehringer Ingelheim GmbH, Eli Lilly and Company, Merck KgaA, Amgen, Inc., AstraZeneca PLC, Actelion Pharmaceuticals Ltd., Shire PLC, AbbVie, Inc., Biocon Ltd., BioMarin Pharmaceutical, Inc., Bristol-Myers Squibb Company, Cipla, Inc.
Regional scope	North America, Europe, Asia-Pacific (APAC), Latin America (LATAM), Middle East & Africa (MEA)
Country scope	U.S., Canada, Germany, France, UK, Italy, Spain, China, India, Japan, Brazil, GCC Countries, South Africa
Key companies profiled	rview The global metabolic disorder therapeutics market size was valued at USD 49.65 billion in 2017 and is expected to register a CAGR of 7.56% over the forecast period. Increasing demand for one-time therapies for metabolic disorders and the rising prevalence of lifestyle diseases are the key factors that are expected to boost the growth of this market. Various governments and healthcare associations around the world have estimated that more than half a billion individuals are to be affected by obesity and diabetes by 2040. Also, rising incidences of inherited metabolic diseases due to changing lifestyles are likely to propel the market growth. As has been observed in recent years, the cases of diabetes have been increasing and many of the countries might face a potential metabolic disorder epidemic. Many of the industrial countries are concerned with the chronic obesity epidemic with the U.S. leading in the number of obese cases. In the U.S. alone, an obese person on average spends around USD 1500 on medical expenses. Over the years, the global economic condition has improved, especially in developing countries, which have a high number of cases of metabolic diseases. Researchers are urging governments across the globe to take action and come up with studies and solutions to reduce obesity and diabetes. For instance, scientists say that one in three individuals is obese and there have never been reports stating the reduction in obesity numbers. These factors are driving obesity segment growth. Other factors that are propelling the market growth are the rapidly aging population, sedentary lifestyles, and increasing cases of smoking and other metabolic pathway restricting practices. Diabetes has become a global epidemic with more than 5% of the population affected by the disease requiring constant medication to battle certain fatal conditions. For instance, in 2016, around 1.5 million deaths occurred directly due to diabetes. Disease Insights Based on disease, the market is categorized into diabetes, lysosomal disorders, hypercholesterolemia, obesity, and inherited metabolic disorders. These diseases are mostly inherited from the older generation through a faulty gene and some show immediate effects like the lysosomal disorders, while some show up later due to aging. For instance, diabetes might not be diagnosed up to a certain age. Diabetes was estimated to be the largest segment in 2017 due to the wide usage of metabolic disease therapies in anti-diabetic drugs and injections to control the blood sugar levels. In diabetes, constant ingestion of metabolic regulators is essential. This factor makes it the largest revenue-generating segment. However, the obesity segment is expected to witness the fastest growth over the forecast period due to increasing lifestyle changes and unhealthy eating habits. Therapy Insights The therapy segment is further categorized into enzyme replacement therapy, cellular transplantation, substrate reduction therapy, small molecule-based therapy, gene therapy, and drug therapy. Except for drug therapy, all the other therapies are novel and cutting-edge, which makes then more effective in treating metabolic diseases. However, the downside of these therapies is high costs and a lack of solid scientific backup. For instance, enzyme replacement therapy costs around 300,000 per year as the treatment should go on continuously at least once or twice a week. Thus, drug therapy held the highest market share due to its extensive usage as a result if ease of administration and high-reliability rate. This therapy is expected to maintain its growth even during the forecast period owing to its advanced ways of administering medications without disturbing day-to-day patient lives. Moreover, the introduction of smart drug delivery devices and smart dosage control methods are projected to drive the segment further. Route of Administration Insights Based on the route of administration, the market is segmented into oral, parenteral, and other routes of administration. The oral route of administration segment was the key revenue-generating segment due to wide usage in diabetes and hypercholesterolemia treatments. The rise in demand for safe and smart drug delivery has driven the growth in this segment because of the ease of use, reliability, and proven results offered by the oral route of administration. The other segment is also likely to witness significant growth over the forecast period as researchers are continuously striving for better medication and therapy that can eliminate the need for lifelong diagnosis and multiple dosage therapy. In recent years, due to the advances in diagnostics, greater emphasis on groundbreaking therapies, like gene therapy, has been observed. This is projected to lead the segment growth shortly. Regional Insights North America is the dominant region of this market due to the presence of major companies. Increasing prevalence of obesity and diabetes in the region is another factor responsible for its largest share. High healthcare expenditure and rising awareness about metabolic disorders are expected to drive the regional market further. Asia Pacific is said to witness the fastest CAGR of 8.27% during the estimated time owing to the rapid economic development in this region. Changing lifestyles, leading to a rise in obesity, diabetes, and hypercholesterolemia diseases, along with increased disposable income levels are driving the APAC market. Market Share Insights Expansion of product portfolios and M&A are the key strategies undertaken by most of these companies. For instance, in 2017, Boehringer Ingelheim, in collaboration with Eli Lily and Company, had announced positive data about the clinical development of Jardiance for the reduction of cardiovascular deaths in adults with type 2 diabetes and peripheral artery disease. KEY MARKET SEGMENTS By Disease Lysosomal Storage Diseases Gaucher’s Disease Metachromatic Leukodystrophy Hurler - Scheie Sanfilipo A Others Diabetes Obesity Inherited Metabolic Disorders Hypercholesterolemia By Therapy Type Enzyme Replacement Therapy Cellular Transplantation Small Molecule Based Therapy Substrate Reduction Therapy Gene Therapy Drug Therapy Route of Administration Oral Parenteral Others By Regional North America The U.S. Canada Europe Germany U.K. Asia Pacific Japan China Latin America Brazil Middle East & Africa South Africa KEY MARKET PLAYERS Novo Nordisk A/S Sanofi S.A. Boehringer Ingelheim GmbH Eli Lilly and Company Merck KgaA Amgen, Inc. AstraZeneca PLC Actelion Pharmaceuticals Ltd. Shire PLC AbbVie, Inc. Biocon Ltd. BioMarin Pharmaceutical, Inc. Bristol-Myers Squibb Company Cipla, Inc. CymaBay Therapeutics, Inc."
Customization scope	Free report customization (15% Free customization) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Reap the benefits of customized purchase options to fit your specific research requirements.

Objectives of the Study

To forecast the market size, in terms of value, for various segments with respect to five main regions, namely, North America, Europe, Asia-Pacific (APAC), Latin America (LATAM), Middle East & Africa (MEA)
To provide detailed information regarding the major factors influencing the growth of the Market (drivers, restraints, opportunities, and challenges)
To strategically analyze the micro markets with respect to the individual growth trends, future prospects, and contribution to the total market
To provide a detailed overview of the value chain and analyze market trends with the Porter's five forces analysis
To analyze the opportunities in the market for various stakeholders by identifying the high-growth Segments
To identify the key players and comprehensively analyze their market position in terms of ranking and core competencies, along with detailing the competitive landscape for the market leaders
To analyze competitive development such as joint ventures, mergers and acquisitions, new product launches and development, and research and development in the market

What does this Report Deliver?

Market Estimation for 20+ Countries
Historical data coverage: 2016 to 2022
Growth projections: 2022 to 2028
SkyQuest's premium market insights: Innovation matrix, IP analysis, Production Analysis, Value chain analysis, Technological trends, and Trade analysis
Customization on Segments, Regions, and Company Profiles
100+ tables, 150+ Figures, 10+ matrix
Global and Country Market Trends
Comprehensive Mapping of Industry Parameters
Attractive Investment Proposition
Competitive Strategies Adopted by Leading Market Participants
Market drivers, restraints, opportunities, and its impact on the market
Regulatory scenario, regional dynamics, and insights of leading countries in each region
Segment trends analysis, opportunity, and growth
Opportunity analysis by region and country
Porter's five force analysis to know the market's condition
Pricing analysis
Parent market analysis
Product portfolio benchmarking

Table Of Content

Executive Summary

Market overview

Exhibit: Executive Summary – Chart on Market Overview
Exhibit: Executive Summary – Data Table on Market Overview
Exhibit: Executive Summary – Chart on Metabolic Disorder Therapeutics Market Characteristics
Exhibit: Executive Summary – Chart on Market by Geography
Exhibit: Executive Summary – Chart on Market Segmentation
Exhibit: Executive Summary – Chart on Incremental Growth
Exhibit: Executive Summary – Data Table on Incremental Growth
Exhibit: Executive Summary – Chart on Vendor Market Positioning

Parent Market Analysis

Market overview

Market size

Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
  - Drivers
  - Opportunities
  - Restraints
  - Challenges
SWOT Analysis

KEY MARKET INSIGHTS

Technology Analysis
- (Exhibit: Data Table: Name of technology and details)
Pricing Analysis
- (Exhibit: Data Table: Name of technology and pricing details)
Supply Chain Analysis
- (Exhibit: Detailed Supply Chain Presentation)
Value Chain Analysis
- (Exhibit: Detailed Value Chain Presentation)
Ecosystem Of the Market
- Exhibit: Parent Market Ecosystem Market Analysis
- Exhibit: Market Characteristics of Parent Market
IP Analysis
- (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
Trade Analysis
- (Exhibit: Data Table: Import and Export data details)
Startup Analysis
- (Exhibit: Data Table: Emerging startups details)
Raw Material Analysis
- (Exhibit: Data Table: Mapping of key raw materials)
Innovation Matrix
- (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
Pipeline product Analysis
- (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
Macroeconomic Indicators

COVID IMPACT

Introduction
Impact On Economy—scenario Assessment
- Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
Revised Market Size
- Exhibit: Data Table on Metabolic Disorder Therapeutics Market size and forecast 2021-2027 ($ million)
Impact Of COVID On Key Segments
- Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
COVID Strategies By Company
- Exhibit: Analysis on key strategies adopted by companies

MARKET DYNAMICS & OUTLOOK

Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
  - Drivers
  - Opportunities
  - Restraints
  - Challenges
Regulatory Landscape
- Exhibit: Data Table on regulation from different region
SWOT Analysis
Porters Analysis
- Competitive rivalry
  - Exhibit: Competitive rivalry Impact of key factors, 2021
- Threat of substitute products
  - Exhibit: Threat of Substitute Products Impact of key factors, 2021
- Bargaining power of buyers
  - Exhibit: buyers bargaining power Impact of key factors, 2021
- Threat of new entrants
  - Exhibit: Threat of new entrants Impact of key factors, 2021
- Bargaining power of suppliers
  - Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
Skyquest special insights on future disruptions
- Political Impact
- Economic impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Market Size by Region

Chart on Market share by geography 2021-2027 (%)
Data Table on Market share by geography 2021-2027(%)
North America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- USA
  - Exhibit: Chart on Market share 2021-2027 (%)
  - Exhibit: Market size and forecast 2021-2027 ($ million)
- Canada
  - Exhibit: Chart on Market share 2021-2027 (%)
  - Exhibit: Market size and forecast 2021-2027 ($ million)
Europe
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Germany
  - Exhibit: Chart on Market share 2021-2027 (%)
  - Exhibit: Market size and forecast 2021-2027 ($ million)
- Spain
  - Exhibit: Chart on Market share 2021-2027 (%)
  - Exhibit: Market size and forecast 2021-2027 ($ million)
- France
  - Exhibit: Chart on Market share 2021-2027 (%)
  - Exhibit: Market size and forecast 2021-2027 ($ million)
- UK
  - Exhibit: Chart on Market share 2021-2027 (%)
  - Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Europe
  - Exhibit: Chart on Market share 2021-2027 (%)
  - Exhibit: Market size and forecast 2021-2027 ($ million)
Asia Pacific
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- China
  - Exhibit: Chart on Market share 2021-2027 (%)
  - Exhibit: Market size and forecast 2021-2027 ($ million)
- India
  - Exhibit: Chart on Market share 2021-2027 (%)
  - Exhibit: Market size and forecast 2021-2027 ($ million)
- Japan
  - Exhibit: Chart on Market share 2021-2027 (%)
  - Exhibit: Market size and forecast 2021-2027 ($ million)
- South Korea
  - Exhibit: Chart on Market share 2021-2027 (%)
  - Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Asia Pacific
  - Exhibit: Chart on Market share 2021-2027 (%)
  - Exhibit: Market size and forecast 2021-2027 ($ million)
Latin America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Brazil
  - Exhibit: Chart on Market share 2021-2027 (%)
  - Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of South America
  - Exhibit: Chart on Market share 2021-2027 (%)
  - Exhibit: Market size and forecast 2021-2027 ($ million)
Middle East & Africa (MEA)
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- GCC Countries
  - Exhibit: Chart on Market share 2021-2027 (%)
  - Exhibit: Market size and forecast 2021-2027 ($ million)
- South Africa
  - Exhibit: Chart on Market share 2021-2027 (%)
  - Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of MEA
  - Exhibit: Chart on Market share 2021-2027 (%)
  - Exhibit: Market size and forecast 2021-2027 ($ million)

KEY COMPANY PROFILES

Competitive Landscape
- Total number of companies covered
  - Exhibit: companies covered in the report, 2021
- Top companies market positioning
  - Exhibit: company positioning matrix, 2021
- Top companies market Share
  - Exhibit: Pie chart analysis on company market share, 2021(%)
rview
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
The global metabolic disorder therapeutics market size was valued at USD 49.65 billion in 2017 and is expected to register a CAGR of 7.56% over the forecast period. Increasing demand for one-time therapies for metabolic disorders and the rising prevalence of lifestyle diseases are the key factors that are expected to boost the growth of this market. Various governments and healthcare associations around the world have estimated that more than half a billion individuals are to be affected by obesity and diabetes by 2040. Also, rising incidences of inherited metabolic diseases due to changing lifestyles are likely to propel the market growth.
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
As has been observed in recent years, the cases of diabetes have been increasing and many of the countries might face a potential metabolic disorder epidemic. Many of the industrial countries are concerned with the chronic obesity epidemic with the U.S. leading in the number of obese cases. In the U.S. alone, an obese person on average spends around USD 1500 on medical expenses.
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
Over the years, the global economic condition has improved, especially in developing countries, which have a high number of cases of metabolic diseases. Researchers are urging governments across the globe to take action and come up with studies and solutions to reduce obesity and diabetes. For instance, scientists say that one in three individuals is obese and there have never been reports stating the reduction in obesity numbers. These factors are driving obesity segment growth.
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
Other factors that are propelling the market growth are the rapidly aging population, sedentary lifestyles, and increasing cases of smoking and other metabolic pathway restricting practices. Diabetes has become a global epidemic with more than 5% of the population affected by the disease requiring constant medication to battle certain fatal conditions. For instance, in 2016, around 1.5 million deaths occurred directly due to diabetes.
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
Disease Insights
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
Based on disease, the market is categorized into diabetes, lysosomal disorders, hypercholesterolemia, obesity, and inherited metabolic disorders. These diseases are mostly inherited from the older generation through a faulty gene and some show immediate effects like the lysosomal disorders, while some show up later due to aging. For instance, diabetes might not be diagnosed up to a certain age.
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
Diabetes was estimated to be the largest segment in 2017 due to the wide usage of metabolic disease therapies in anti-diabetic drugs and injections to control the blood sugar levels. In diabetes, constant ingestion of metabolic regulators is essential. This factor makes it the largest revenue-generating segment. However, the obesity segment is expected to witness the fastest growth over the forecast period due to increasing lifestyle changes and unhealthy eating habits.
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
Therapy Insights
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
The therapy segment is further categorized into enzyme replacement therapy, cellular transplantation, substrate reduction therapy, small molecule-based therapy, gene therapy, and drug therapy. Except for drug therapy, all the other therapies are novel and cutting-edge, which makes then more effective in treating metabolic diseases. However, the downside of these therapies is high costs and a lack of solid scientific backup. For instance, enzyme replacement therapy costs around 300,000 per year as the treatment should go on continuously at least once or twice a week.
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
Thus, drug therapy held the highest market share due to its extensive usage as a result if ease of administration and high-reliability rate. This therapy is expected to maintain its growth even during the forecast period owing to its advanced ways of administering medications without disturbing day-to-day patient lives. Moreover, the introduction of smart drug delivery devices and smart dosage control methods are projected to drive the segment further.
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
Route of Administration Insights
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
Based on the route of administration, the market is segmented into oral, parenteral, and other routes of administration. The oral route of administration segment was the key revenue-generating segment due to wide usage in diabetes and hypercholesterolemia treatments. The rise in demand for safe and smart drug delivery has driven the growth in this segment because of the ease of use, reliability, and proven results offered by the oral route of administration.
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
The other segment is also likely to witness significant growth over the forecast period as researchers are continuously striving for better medication and therapy that can eliminate the need for lifelong diagnosis and multiple dosage therapy. In recent years, due to the advances in diagnostics, greater emphasis on groundbreaking therapies, like gene therapy, has been observed. This is projected to lead the segment growth shortly.
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
Regional Insights
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
North America is the dominant region of this market due to the presence of major companies. Increasing prevalence of obesity and diabetes in the region is another factor responsible for its largest share. High healthcare expenditure and rising awareness about metabolic disorders are expected to drive the regional market further.
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
Asia Pacific is said to witness the fastest CAGR of 8.27% during the estimated time owing to the rapid economic development in this region. Changing lifestyles, leading to a rise in obesity, diabetes, and hypercholesterolemia diseases, along with increased disposable income levels are driving the APAC market.
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
Market Share Insights
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
Expansion of product portfolios and M&A are the key strategies undertaken by most of these companies. For instance, in 2017, Boehringer Ingelheim, in collaboration with Eli Lily and Company, had announced positive data about the clinical development of Jardiance for the reduction of cardiovascular deaths in adults with type 2 diabetes and peripheral artery disease.
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
KEY MARKET SEGMENTS
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
By Disease
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
Lysosomal Storage Diseases
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
Gaucher’s Disease
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
Metachromatic Leukodystrophy
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
Hurler - Scheie
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
Sanfilipo A
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
Others
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
Diabetes
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
Obesity
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
Inherited Metabolic Disorders
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
Hypercholesterolemia
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
By Therapy Type
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
Enzyme Replacement Therapy
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
Cellular Transplantation
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
Small Molecule Based Therapy
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
Substrate Reduction Therapy
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
Gene Therapy
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
Drug Therapy
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
Route of Administration
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
Oral
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
Parenteral
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
Others
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
By Regional
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
North America
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
The U.S.
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
Canada
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
Europe
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
Germany
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
U.K.
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
Asia Pacific
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
Japan
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
China
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
Latin America
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
Brazil
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
Middle East & Africa
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
South Africa
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
KEY MARKET PLAYERS
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
Novo Nordisk A/S
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
Sanofi S.A.
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
Boehringer Ingelheim GmbH
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
Eli Lilly and Company
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
Merck KgaA
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
Amgen, Inc.
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
AstraZeneca PLC
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
Actelion Pharmaceuticals Ltd.
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
Shire PLC
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
AbbVie, Inc.
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
Biocon Ltd.
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
BioMarin Pharmaceutical, Inc.
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
Bristol-Myers Squibb Company
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
Cipla, Inc.
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments
CymaBay Therapeutics, Inc."
- Exhibit Company Overview
- Exhibit Business Segment Overview
- Exhibit Financial Updates
- Exhibit Key Developments

Methodology

For the Metabolic Disorder Therapeutics Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:

1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.

2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Metabolic Disorder Therapeutics Market.

3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.

4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.

Analyst Support

Customization Options

With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Metabolic Disorder Therapeutics Market:

Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.

Regional Analysis: Further analysis of the Metabolic Disorder Therapeutics Market for additional countries.

Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.

Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.

Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.

Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.

Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.

Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.

Metabolic Disorder Therapeutics Market Report Snapshots

License Type Top market research company in USA

File Type

$5,300

BUY NOW

REQUEST FOR SAMPLE

Want to customize this report?

REQUEST FREE CUSTOMIZATION

FAQs

The market for Metabolic Disorder Therapeutics was estimated to be valued at US$ XX Mn in 2021.

The Metabolic Disorder Therapeutics Market is estimated to grow at a CAGR of XX% by 2028.

The Metabolic Disorder Therapeutics Market is segmented on the basis of Disease, Therapy Type, Regional.

Based on region, the Metabolic Disorder Therapeutics Market is segmented into North America, Europe, Asia Pacific, Middle East & Africa and Latin America.

The key players operating in the Metabolic Disorder Therapeutics Market are rview , The metabolic disorder therapeutics market size was valued at USD 49.65 billion in 2017 and is expected to register a CAGR of 7.56% over the forecast period. Increasing demand for one-time therapies for metabolic disorders and the rising prevalence of lifestyle diseases are the key factors that are expected to boost the growth of this market. Various governments and healthcare associations around the world have estimated that more than half a billion individuals are to be affected by obesity and diabetes by 2040. Also, rising incidences of inherited metabolic diseases due to changing lifestyles are likely to propel the market growth. , As has been observed in recent years, the cases of diabetes have been increasing and many of the countries might face a potential metabolic disorder epidemic. Many of the industrial countries are concerned with the chronic obesity epidemic with the U.S. leading in the number of obese cases. In the U.S. alone, an obese person on average spends around USD 1500 on medical expenses. , Over the years, the economic condition has improved, especially in developing countries, which have a high number of cases of metabolic diseases. Researchers are urging governments across the globe to take action and come up with studies and solutions to reduce obesity and diabetes. For instance, scientists say that one in three individuals is obese and there have never been reports stating the reduction in obesity numbers. These factors are driving obesity segment growth. , Other factors that are propelling the market growth are the rapidly aging population, sedentary lifestyles, and increasing cases of smoking and other metabolic pathway restricting practices. Diabetes has become a epidemic with more than 5% of the population affected by the disease requiring constant medication to battle certain fatal conditions. For instance, in 2016, around 1.5 million deaths occurred directly due to diabetes. , Disease Insights , Based on disease, the market is categorized into diabetes, lysosomal disorders, hypercholesterolemia, obesity, and inherited metabolic disorders. These diseases are mostly inherited from the older generation through a faulty gene and some show immediate effects like the lysosomal disorders, while some show up later due to aging. For instance, diabetes might not be diagnosed up to a certain age. , Diabetes was estimated to be the largest segment in 2017 due to the wide usage of metabolic disease therapies in anti-diabetic drugs and injections to control the blood sugar levels. In diabetes, constant ingestion of metabolic regulators is essential. This factor makes it the largest revenue-generating segment. However, the obesity segment is expected to witness the fastest growth over the forecast period due to increasing lifestyle changes and unhealthy eating habits. , Therapy Insights , The therapy segment is further categorized into enzyme replacement therapy, cellular transplantation, substrate reduction therapy, small molecule-based therapy, gene therapy, and drug therapy. Except for drug therapy, all the other therapies are novel and cutting-edge, which makes then more effective in treating metabolic diseases. However, the downside of these therapies is high costs and a lack of solid scientific backup. For instance, enzyme replacement therapy costs around 300,000 per year as the treatment should go on continuously at least once or twice a week. , Thus, drug therapy held the highest market share due to its extensive usage as a result if ease of administration and high-reliability rate. This therapy is expected to maintain its growth even during the forecast period owing to its advanced ways of administering medications without disturbing day-to-day patient lives. Moreover, the introduction of smart drug delivery devices and smart dosage control methods are projected to drive the segment further. , Route of Administration Insights , Based on the route of administration, the market is segmented into oral, parenteral, and other routes of administration. The oral route of administration segment was the key revenue-generating segment due to wide usage in diabetes and hypercholesterolemia treatments. The rise in demand for safe and smart drug delivery has driven the growth in this segment because of the ease of use, reliability, and proven results offered by the oral route of administration. , The other segment is also likely to witness significant growth over the forecast period as researchers are continuously striving for better medication and therapy that can eliminate the need for lifelong diagnosis and multiple dosage therapy. In recent years, due to the advances in diagnostics, greater emphasis on groundbreaking therapies, like gene therapy, has been observed. This is projected to lead the segment growth shortly. , Regional Insights , North America is the dominant region of this market due to the presence of major companies. Increasing prevalence of obesity and diabetes in the region is another factor responsible for its largest share. High healthcare expenditure and rising awareness about metabolic disorders are expected to drive the regional market further. , Asia Pacific is said to witness the fastest CAGR of 8.27% during the estimated time owing to the rapid economic development in this region. Changing lifestyles, leading to a rise in obesity, diabetes, and hypercholesterolemia diseases, along with increased disposable income levels are driving the APAC market. , Market Share Insights , Expansion of product portfolios and M&A are the key strategies undertaken by most of these companies. For instance, in 2017, Boehringer Ingelheim, in collaboration with Eli Lily and Company, had announced positive data about the clinical development of Jardiance for the reduction of cardiovascular deaths in adults with type 2 diabetes and peripheral artery disease. , KEY MARKET SEGMENTS, By Disease, Lysosomal Storage Diseases , Gaucher’s Disease , Metachromatic Leukodystrophy , Hurler - Scheie , Sanfilipo A , Others , Diabetes , Obesity , Inherited Metabolic Disorders , Hypercholesterolemia , By Therapy Type, Enzyme Replacement Therapy , Cellular Transplantation , Small Molecule Based Therapy , Substrate Reduction Therapy , Gene Therapy , Drug Therapy , Route of Administration, Oral , Parenteral , Others , By Regional, North America , The U.S. , Canada , Europe , Germany , U.K. , Asia Pacific , Japan , China , Latin America , Brazil , Middle East & Africa , South Africa , KEY MARKET PLAYERS, Novo Nordisk A/S , Sanofi S.A. , Boehringer Ingelheim GmbH , Eli Lilly and Company , Merck KgaA , Amgen, Inc. , AstraZeneca PLC , Actelion Pharmaceuticals Ltd. , Shire PLC , AbbVie, Inc. , Biocon Ltd. , BioMarin Pharmaceutical, Inc. , Bristol-Myers Squibb Company , Cipla, Inc. , CymaBay Therapeutics, Inc.".

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

Metabolic Disorder Therapeutics Market

Report ID: UCMIG35I2238

sales@skyquestt.com
USA +1 351-333-4748

BUY NOW GET FREE SAMPLE